Merck to acquire HUB Organoids to advance cell culture portfolio

Acquisition to advance company's next generation biology portfolio with internationally recognized pioneer in organoid development

AbbVie announces emotional impact report on mental health of underrepresented CLL cancer patients

CLL is one of the most common leukemias among adults affecting more than 200,000 people in the US

Shilpa Medicare’s JV Oncosol gets USFDA approval for IMKELDI

IMKELDI is an advanced liquid formulation of imatinib designed to provide dosing accuracy

DKSH and Abcam join forces to advance life science research in Vietnam

This partnership is set to meet the growing demand for innovative life science research solutions in the Vietnamese market

USFDA approves first gene therapy for treatment of aromatic L-amino acid decarboxylase deficiency

Aromatic L-amino acid decarboxylase deficiency is a rare genetic disorder that affects the production of some neurotransmitters

Shilpa Medicare’s acceptance by USFDA of NDA filed by its CDMO partner Unicycive for Oxylanthanum Carbonate

GSK to acquire CMG1A46 from Chimagen Biosciences to expand immunology pipeline

CMG1A46 is an investigational T cell-engager with potential to deeply deplete uncontrolled B cells present in autoimmune diseases such as lupus

Roche’s Vabysmo improved vision in underrepresented populations with DME in a first-of-its-kind study

Efficacy and safety from this phase IV study were consistent with data from the Vabysmo phase III DME studies

Tim Buckley elected to Pfizer’s Board of Directors

Buckley served as Chairman and Chief Executive Officer at Vanguard from 2018 until his retirement in 2024

Zydus and ICMR initiate a Phase 2 trial of Desidustat in patients with Sickle Cell Disease

The partnership marks a pivotal step towards developing new therapies for combating Sickle Cell Disease